Drug Trial Radar · NCT04027309
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
777
Actual
Start
Dec 20, 2019
Primary completion
Oct 2025
Study completion Jun 2033
Sponsor
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG); Astellas Pharma Global Development, Inc.
- First posted
- Jul 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML). Addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib is a more potent and more specific inhibitor of mutant FLT3 in comparison to midostaurin and has shown promising clinical activity in AML.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts-2
Interventions
GilteritinibDrug
Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
MidostaurinDrug
Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overal survival (OS)Time frame: Approximately up to 70 months following first patient enrolment
Locations
193 sites in 13 countries. Site status is shown where the registry gives one.
AU-Adelaide-FLINDERS
Adelaide, Australia
AU-Adelaide-RAH
Adelaide, Australia
AU-Brisbane-PAH
Brisbane, Australia
AU-Brisbane-RBWH
Brisbane, Australia
AU-Camperdown-RPA
Camperdown, Australia
AU-Douglas-TOWNSVILLE
Douglas, Australia
AU-Geelong VIC-BARWONHEALTH
Geelong, Australia
AU-Gosford NSW-GOSFORDHOSPITAL
Gosford, Australia
AU-Hobart TAS-RHOBART
Hobart, Australia
AU-Melbourne-ALFRED
Melbourne, Australia
AU-Melbourne-AUSTIN
Melbourne, Australia
AU-Melbourne-BOXHILL
Melbourne, Australia
AU-Melbourne-MONASH
Melbourne, Australia
AU-Melbourne-RMELBOURNE
Melbourne, Australia
AU-Melbourne-SVHM
Melbourne, Australia
AU-Perth-FSH
Perth, Australia
AU-Perth-RPH
Perth, Australia
AU-Perth-SCGH
Perth, Australia
AU-Sydney-CONCORD
Sydney, Australia
AU-Sydney-NEPEAN
Sydney, Australia
AU-Sydney-RNSH
Sydney, Australia
AU-Sydney-WSAH
Sydney, Australia
St George Hospital
Sydney, Australia
AU-Waratah-CALVARYMATER
Waratah, Australia
AT-Graz-MEDUNIGRAZ
Graz, Austria
AT-Innsbruck-IMED
Innsbruck, Austria
AT-Linz-KEPLER
Linz, Austria
AT-Linz-ORDENSKLINIKUM
Linz, Austria
AT-Salzburg-SALK
Salzburg, Austria
AT-Vienna-HANUSCH
Vienna, Austria
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
BE-Brugge-AZBRUGGE
Bruges, Belgium
BE-Brussel-BORDET
Brussels, Belgium
BE-Bruxelles-STLUC
Brussels, Belgium
BE-Gent-UZGENT
Ghent, Belgium
BE-Haine-Saint-Paul-JOLIMONT
Haine-Saint-Paul, Belgium
BE-Hasselt-VIRGAJESSE
Hasselt, Belgium
BE-Leuven-UZLEUVEN
Leuven, Belgium
BE-Liege-CHRCITADELLE
Liège, Belgium
BE-Liege-CHULIEGE
Liège, Belgium
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.